A preclinical study published in Impact Journals has introduced a highly promising therapeutic strategy for reversing cellular senescence in aging tissues. By applying a targeted topical senolytic drug known as ABT-263 directly to the skin, scientists successfully eliminated damaged cells and stimulated collagen production along with new blood vessel growth. The innovative treatment dramatically boosted wound recovery rates in older subjects, opening up incredible possibilities for enhancing preoperative care and managing chronic skin conditions in elderly patients.
About the Author
